Calendario›ELTX›ELI-002 7P · AMPLIFY-EAP
ELI-002 7P · AMPLIFY-EAP
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
Ensayo de Elicio Therapeutics, Inc. en Pancreatic Ductal Adenocarcinoma · KRAS G12D · KRAS G12V · KRAS G12S · KRAS G12A · KRAS G12C · KRAS G12R · KRAS G13D · NRAS G12D · NRAS G12V · NRAS G12S · NRAS G12A · NRAS G12C · NRAS G12R · NRAS G13D (del registro, en inglés).
Más ensayos de: Adenocarcinoma ductal de páncreas.
Lo que ha anunciado la empresa
La empresa anunció que NO alcanzó su objetivo principal…of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026 • While Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic ductal adenocarcinoma…
En un 8-K del 13 ago 2026, en una frase que nombra «ELI-002 7P». El documento en la SEC.
La empresa anunció que NO alcanzó su objetivo principal…06x15xxeltxxxph2re.htm EX-99.1 Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer • AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population. • Randomization balanced most prognostic factors between arms. However, the ELI-002 7P arm had a higher proportion of R1 resected (higher…
En un 8-K del 15 jun 2026, en una frase que nombra «ELI-002 7P». El documento en la SEC.
- Fase
- no aplica
- Estado
- Ya no disponible
Qué significa cada fase y cada estado.
Estudio de acceso ampliado.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is an open-label expanded access protocol (EAP) of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in patients with KRAS/NRAS-mutated pancreatic ductal adenocarcinoma who are at high risk for relapse (ie, presence of isolated tumor cells in a patient whose primary tumor has been removed and is currently without clinical signs of disease). This protocol builds on the experience being obtained with ELI-002 7P (with Amph-Peptides G12D, G12R, G12V, G12A, G12C, G12S, G13D), which is being studied in protocol ELI-002-201.
Más ensayos de ELTX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| ELI-002 7P · AMPLIFY-7P | Fase 1/2 | En marcha, sin reclutar | abr 2026 (real) |
| ELI-002 2P · AMPLIFY-201 | Fase 1 | Completado | ene 2023 (real) |
Todos los de ELTX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07083479), actualizada en jul 2026.